Melasma: Treatment strategy

Journal of Cosmetic and Laser Therapy

Volumn 13, Issue 6, 2011, Pages 265-279

  Sehgal, Virendra N ^a   Verma, Prashant ^b   Srivastava, Govind ^b   Aggarwal, Ashok K ^b   Verma, Sangeeta ^b  

^a Sehgal Nursing Home   (India)

^b NONE

Author keywords

Clinical connotation; Diagnosis; Epidemiology; Etio pathogenesis; Melasma; Treatment strategy

Indexed keywords

AMIODARONE; ASCORBIC ACID; AZELAIC ACID; BLEOMYCIN; BUSULFAN; CHAMOMILLA RECUTITA EXTRACT; CHLOROQUINE; CHLORPROMAZINE; CLOFAZIMINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ELLAGIC ACID; FOLLITROPIN; HYDANTOIN; HYDROQUINONE; INDOMETACIN; INTERMEDIN; KOJIC ACID; LUTEINIZING HORMONE; MINOCYCLINE; ORAL CONTRACEPTIVE AGENT; PLACENTA EXTRACT; PROGESTERONE; PROLACTIN; RETINOIC ACID; SUNSCREEN; THYROID HORMONE; TRANEXAMIC ACID; UNINDEXED DRUG; ZIDOVUDINE;

ACNE; ADDISON DISEASE; CHLOASMA; CONTACT DERMATITIS; DIFFERENTIAL DIAGNOSIS; ELASTOSIS; ELECTRON MICROSCOPY; FIXED DRUG ERUPTION; HISTOPATHOLOGY; HUMAN; HYPERPIGMENTATION; IMMUNOHISTOCHEMISTRY; LICHEN PLANUS; LOW LEVEL LASER THERAPY; MEDLINE; MELANOCYTE; MELANOSOME; MONOTHERAPY; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; REVIEW; SKIN IRRITATION; TEA; TELANGIECTASIA;

CHEMEXFOLIATION; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; FACE; FEMALE; HUMANS; LASER THERAPY, LOW-LEVEL; MELANOSIS; SEVERITY OF ILLNESS INDEX; SUNSCREENING AGENTS;

EID: 81455133724     PISSN: 14764172     EISSN: 14764180     Source Type: Journal    
DOI: 10.3109/14764172.2011.630088     Document Type: Review

References (161)

1. McDonald RR, Georgouras KE. Skin Disorders in Indo-Chinese immigrants. Med J Aust. 1992;156:847-853.
2. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ. 1999;318:593-596.
3. Sarkar R, Puri P, Jain RK, Singh A, Desai A. Melasma in men: a clinical, aetiological and histological study. J Eur Acad Dermatol Venereol. 2010;24:768-772.
4. Sanchez NP, Pathak MA, Sato S, Fitzpatrick TB, Sanchez JL, et al. Melasma: A clinical light microscopic, ultrastructural, and immunofl uorescence study. J Am Acad Dermatol. 1981;4:698-710. (Pubitemid 11038002)
5. Moin A, Jabery Z, Fallah A. Prevalence and awareness of melasma during pregnancy. Int J Dermatol. 2006;45: 285-288. (Pubitemid 43337644)
6. Goh CL, Dlova CN. A retrospective study on the clinical presentation and treatment outcome of melasma in a tertiary dermatological referral centre in Singapore. Singapore Med J. 1999;40:455-488.
7. Abaraca J. Melasma in pregnancy. Med Cutan Iberolat Am. 1987;15:199-203.
8. Adalatkhah H, Sedeghi-bazargani H, Amini-sani N, Zeynizadeh S. Melasma and its association with different types of nevi in women: A case control study. BMC Dermaotol. 2008;8:3.
9. Muzaffar F, Hussain I, Haroon TS. Physiologic skin changes during pregnancy: A study of 140 cases. Int J Dermatol. 1998;37:429-431. (Pubitemid 28284870)
10. Ortonne JP, Arellano I, Berneburg M, Cestari T, Chan H, et al. A global survey of the role of ultraviolet radiation and hormonal infl uences in the development of melasma. J Eur Acad Dermatol Venereol. 2009;23:1254-1262.
11. Halaban R, Hebert DN, Fisher DE. Biology of melanocytes. In: Freedberg IM, Eisen AZ, Wolff K, Austen FK, Goldsmith LA, Katz SI, editors. Dermatology In General Medicine. 6th ed. New York, NY: McGraw Hill Medical Publishing; 2003. pp. 127 - 148.
12. Ortonne JP, Bahadoran P, Fitzpatrick TB, et al. Hypomelanosis and hypermelanosis. In: Freedman IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, editors. Fitzpatrick's Dermatology in General Medicine. McGraw Hill: New York; 2003. pp. 836 - 881.
13. Ando H, Ryu A, Hashimoto A, Oka M, Ichihashi M. Linoleic acid and alpha-linolenic acid lightens ultraviolet-induced hyperpigmentation of the skin. Arch Dermatol Res. 1998;290:375-381. (Pubitemid 28408561)
14. Ando H, Watabe H, Valencia JC, Yasumoto K, Furumura M, et al. Fatty acids regulate pigmentation via proteasomal degradation of tyrosinase: A new aspect of ubiquitin-proteasome function. J Biol Chem. 2004;279:15427-15433. (Pubitemid 38618942)
15. The chemistry of melanin: III. Mechanism of the oxidation of dihydroxyphenylalanine by tyrosinase. Howard S Mason J Biol Chem. 1948;172:83-99.
16. Raper HS. The Aerobic Oxidases. Physiol Rev. 1928;8: 245-258.
17. Pathak MA, Fitzpatrick TB, Kraus EW. Usefulness of retinoic acid in the treatment of melasma. J Am Acad Dermatol. 1986;15:894-899. (Pubitemid 17170795)
18. Im S, Lee ES, Kim W, On W, Kim J, et al. Donor specific response of estrogen and progesterone on cultured human melanocytes. J Korean Med Sci. 2002;17:58-64.
19. Kim NH, Lee CH, Lee AY. H19 RNA downregulation stimulated melanogenesis in melasma. Pigment Cell Melanoma Res. 2010;23:84-92
20. Hernán dez-Barrera R, Torres-Alvarez B, Castanedo-Cazares JP, Oros-Ovalle C, Moncada B. Solar elastosis and presence of mast cells as key features in the pathogenesis of melasma. Clin Exp Dermatol. 2008;33:305-308. (Pubitemid 351550658)
21. Pandya AG, Guevara IL. Disorders of hyperpigmentation. Dermatol Clin. 2001;18:91-98.
22. Cunningham FG, MacDonald PC, Leveno KJ, et al. Maternal adaptations to pregnancy. In: Williams J, ed. Williams Obstrectis. 19th ed. Prentice- Hall, USA; 1993. p. 215.
23. Bolanca I, Bolanca Z, Kuna K, Vukovi A, Tuckar N, et al. Chloasma-the mask of pregnancy. Coll Antropol. 2008;2:139-141.
24. Resnik S. Melasma induced by oral contraceptive drugs. J Am Med Assoc. 1967;199:601-605.
25. Parker F. Skin and hormones. In: Williams RH, ed. Textbook of Endocrinology. 6th ed. Philadelphia: WB Saunders Co; 1981. pp. 1088 - 1091.
26. Johnston GA, Sviland L, McLelland J. Melasma of the arm associated with hormone replacement therapy. Br J Dermatol. 1998;139:932. (Pubitemid 28520320)
27. Esoda E. Chloasma from progestational and contraceptives. Arch Dermatol. 1963;87:486.
28. Perez M, Sanchez JL, Aquilo F. Endocrinologic profi le of patients with idiopathic melasma. J Invest Dermatol. 1983;81:543-545. (Pubitemid 14202316)
29. Jang YH, Lee JY, Kang HY, Lee ES, Kim YC. Oestrogen and progesterone receptor expression in melasma: An immunohistochemical analysis. J Eur Acad Dermatol Venereol. 2010;23: [Epub ahead of print].
30. Lieberman R, Moy L. Estrogen receptor expression in melasma: Results from facial skin of affected patients. J Drugs Dermatol. 2008;7:463-465.
31. Lutfi RJ, Fridmanis M, Misiunas AL, Pafume O, Gonzalez EA, et al. Association of melasma with thyroid autoimmunity and other thyroid abnormalities and their relationship to the origin of melasma. J Clin Endocrinol Metab. 1985;61:28-31. (Pubitemid 15046190)
32. Niepomniszcze H. Amad RH. Skin disorders and thyroid diseases. J Endocrinol Invest. 2001:24:628-638. (Pubitemid 32951855)
33. Sarkany I, Graham-Brown RAC. The hepatobiliary system and the skin. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, editors. Fitzpatrick ' s Dermatology in General Medicine. 4th ed. McGraw Hill; 1999. pp.1972.
34. Bedi TR, Bhutani LK. Aetiological factors in chloasma. Br J Clin Pract. 1975;29:107-108.
35. Kimbrough-Green CK, Griffi ths CEM, Finkel LJ, Hamilton TA, Bulengo-Ransby SM, et al. Topical retinoic acid (tretinoin) for melasma in black patients. Arch Dermatol. 1994;130:727-733.
36. Grimes PE, Yamada N, Bhawan J. Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma. Am. J Dermatopathol. 2005;27:96-101. (Pubitemid 40471093)
37. Hassan I, Kaur I, Sialy R, Dash RJ. Hormonal milieu in the maintenance of melasma in fertile women. J Dermatol. 1998;25:510-512. (Pubitemid 28417199)
38. Kang WH, Yoon KH, Lee ES, Kim J, Lee KB, et al. Melasma: histopathological characteristics in 56 Korean patients. Br J Dermatol. 2002;146:228-237. (Pubitemid 34264392)
39. Kang HY, Hwang JS, Lee JY, Ahn JH, Kim JY, et al. The dermal stem cell factor and c-kit are overexpressed in melasma. Br J Dermatol. 2006;154:1094-1099. (Pubitemid 43727390)
40. Kim EH, Kim YC, Lee ES, Kang HY. The vascular characteristics of melasma. Dermatol Sci. 2007;46:111-116. (Pubitemid 46467289)
41. Sarvjot V, Sharma S, Mishra S, Singh A. Melasma: A clinicopathological study of 43 cases. Indian J Pathol Microbiol. 2009;52:357-359.
42. Grimes PE, Yamada N, Bhawan J. Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma. Am J Dermatopathol. 2005;27:96-101. (Pubitemid 40471093)
43. Aloi F, Solaroli C, Giovannini E. Actinic lichen planus simulating melasma. Dermatology. 1997:195:69-70. (Pubitemid 27326717)
44. Pandya AG, Guevara IL. Disorders of hyperpigmentation. Dermatol Clin. 2000;18:91-98.
45. Piamphongsant T. Treatment of melasma: A review with personal experience. Int J Dermatol. 1998;37:897-903. (Pubitemid 29012777)
46. Serrano G, Pujol C, Cuadra J, Gallo S, Aliaga A. Riehl's melanosis: pigmented contact dermatitis caused by fragrances. J Am Acad Dermatol. 1989;21:1057-1060. (Pubitemid 19266707)
47. Sun CC, Lü YC, Lee EF, Nakagawa H. Naevus fuscocaeruleus zygomaticus. Br J Dermatol. 1987;117:545-553.
48. Sarkar R, Sehgal VN. Skin peel. In: Sehgal VN, ed. Dermatologic surgery made easy. Ist ed. New Delhi: Jaypee; 2006. pp. 17 - 34.
49. Pathak MA, Fitzpatrick TB, Nighiem P, et al. Sun protective agents: Formulations, effects and side effects. In: Freedberg IM, Eisen AZ, Fitzpatrick TB, editors. Dermatology in General Medicine. 5th ed. New York: McGraw Hill Inc; 1999. pp. 2742 - 2763.
50. Diffey BL. When should sunscreen be reapplied. J Am Acad Dermatol. 2001;45:882-885.
51. Rhodes LE. Topical and systemic approaches for protection against solar radiation induced skin damage. Clin Dermatol. 1998;16:75-82. (Pubitemid 28303581)
52. Rendon M, Berneburg M, Arellano I, et al. Treatment of melasma. J Am Acad Dermatol. 2006;54:272-281.
53. Jimbow K, Obata, H, Pathak MA, Fitzpatrick TB. Mechanism of depigmentation by hydroquinone. J Invest Dermatol. 1974;62:436-439.
54. Sanchez JL, Vazquez M. A hydroquinone solution in the treatment of melasma. Int J Dermatol. 1982;21:55-58. (Pubitemid 12171818)
55. V ázquez M, Sá n chez JL. The effi cacy of a broad-spectrumsunscreen in the treatment of melasma. A randomized double blinded controlled trial. Cutis. 1983;32:92-96.
56. Arndt KA, Fitzpatrick TB. Topical use of hydroquinone as a depigmentating agent. JAMA. 1965;194:965-967.
57. Grimes PE. Melasma: Etiologic and therapeutic considerations. Arch Dermatol. 1995;131:1453-1457.
58. Engasser PE, Maibach HI. Cosmetics and dermatology: Bleaching creams. J Am Acad Dermatol. 1981;5: 143-147. (Pubitemid 11016609)
59. Findley GH, Morrison JGL, Simon IW. Exogenous ochronosis and pigmented millium from hydroquinone bleaching creams. Br J Dermatol. 1975;93:613-622.
60. Kligman AM, Willis I. A new formula for depigmenting human skin. Arch Dermatol. 1975;111:40-48.
61. Gano SE, Garcia RL. Topical tretinoin, hydroquinone and betamethasone valerate in the therapy of melasma. Cutis. 1979;23:239-241. (Pubitemid 9114369)
62. Nazzaro-Porro M. Azealic acid. J Am Acad Dermatol. 1987;17:1033-1041.
63. Baliñ a LM, Graupe K. The treatment of melasma. 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol. 1991;30:893-895.
64. Sivayathorn A, Verallo-Rowell V, Graupe K. Eur J Dermatol. 1995;5:680-684.
65. Verallo-Rowell VM, Verallo V, Graupe K, Lopez-Villafuerte L, Garcia-Lopez M. Double blind comparison of azealic acid and hydroquinone in the treatment of melasma. Acta Derm Venereol Suppl. 1989;143:58-61. (Pubitemid 19172051)
66. Kakita LS, Lowe NJ. Azelaic acid and glycolic acid combination therapy for facial hyperpigmentation in darker skinned patients: A clinical comparison with hydroquinone. Clin Ther. 1998;20:960-970. (Pubitemid 28535731)
67. Lerner AB, Fitzpatrick TB. Biochemistry of melanin formation. Physiol Rev. 1950;30:91-126.
68. Njoo MD, Menke HE, Pavel W, et al. N-Acetyl cysteine as a bleaching agent in treatment of melasma. J Eur Acad Derma Venereol. 1997;9:86-87.
69. Orlow SJ, Chakraborty AK, Pawelek JM. Retinoic acid as a potent inhibitor of inducible pigmentation in murine and hamster melanomma cell lines. J Invest Dermatol. 1990;94:461-464. (Pubitemid 20123922)
70. Griffi ths CEM, Finkel LJ, Ditre CM, Hamilton TA, Ellis CN, et al. Topical tretinoin (retinoic acid) improves melasma. A vehicle controlled clinical trial. Br J Dermatol. 1993;129: 415-421. (Pubitemid 23308246)
71. Kimbrough-Green CK, Griffi ths CE, Finkel LJ, Hamilton TA, Bulengo-Ransby SM, et al. Topical retinoic acid (tretinoin) for melasma in black patients. Arch Dermatol. 1994;130:727-733.
72. Griffi ths CE, Finkel LJ, Ditre CM, Hamilton TA, Ellis CN, et al. Topical tretinoin (retinoic acid) improves melasma vehicle-controlled, clinical trial. Br J Dermatol. 1993;129: 415-421. (Pubitemid 23308246)
73. Ghersetich I, Troiano M, Brazzini B, Arunachalam M, Lotti T. Melasma:treatment with 10% tretinoin peeling mask. J Cosmet Dermatol. 2010;9:117-121.
74. Gilchrist BA, Fitzpatrick TB, Anderson RR, Parrish JA. Localization of melanin pigmentation in the skin with the Wood ' s lamp. Br J Dermatol. 1977;96:245-248. (Pubitemid 8072473)
75. Kang HY, Valerio L, Bahadoran P, Ortonne JP. The role of topical retinoids in the treatment of pigmentary disorders: An evidence-based review. Am J Clin Dermatol. 2009;10: 251-260.
76. Kanwar AJ, Dhar S, Kaur S. Treatment of melasma with potent topical corticosteroids. Dermatology. 1994;188:170. (Pubitemid 24031346)
77. Tirado-Sá n chez A, Santamaría-Romá n A, Ponce-Olivera RM. Efficacy of dioic acid compared with hydroquinone in the treatment of melasma. Int J Dermatol. 2009;48:893-895.
78. Tadokoro T, Bonté F, Archambault JC, Cauchard JH, Neveu M, et al. Whitening effi cacy of plant extracts including orchid extracts on Japanese female skin with melasma and lentigo senilis. J Dermatol. 2010;37:522-530.
79. Kligman AM, Willis I. A new formula for depigmenting human skin. Arch Dermatol. 1975;111:40-48.
80. Westerhof W, Njoo MD. Bleaching agents. In: Katsambas AD, Lotti TM, editors. European handbook of dermatological treatments. Berlin: Springer; 1999. pp. 766 - 77.
81. Chan R, Park KC, Lee MH, Lee ES, Chang SE, et al. A randomized controlled trial of the effi cacy and safety of a fixed triple combination (fl uocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. Br J Dermatol. 2008;159:697-703.
82. Grimes PE, Bhawan J, Guevara IL, Colón LE, Johnson LA, et al. Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma. J Am Acad Dermatol. 2010;62:962-967.
83. Pathak MA, Fitzpatrick TB, Kraus EW. Usefulness of retinoic acid in the treatment of melasma. J Am Acad Dermatol. 1986;15:894-899. (Pubitemid 17170795)
84. Taylor SC, Torok H, Jones T, Lowe N, Rich P, et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis. 2003;72:67-72. (Pubitemid 37229761)
85. Garcia A, Fulton JE Jr. The combination of glycolic acid and hydroquinone or kojic acid for the treatment of melasma and related conditions. Dermatol Surg. 1996;22:443-447. (Pubitemid 26153095)
86. Kameyama K, Sakai C, Kondoh S. Inhibitory effects of magnesium-L- ascorbyl-2-phosphate (VC- PMG) on melanogenesis in- vitro and in-vivo. J Am Acad Dermatol. 1996;34:29-33. (Pubitemid 26049894)
87. Espinal-Perez LE, Moncada B, Castanedo-Cazares JP. A doubleblind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma. Int. J Dermatol. 2004;43: 604-607. (Pubitemid 39207001)
88. Hwang SW, Oh DJ, Lee D, Kim JW, Park SW. Clinical efficacy of 25% L-ascorbic acid (C'ensil) in the treatment of melasma. J Cutan Med Surg. 2009;13:74-81.
89. Itoh H. Functions and whitening effect of placenta. Fragrance J. 1990;6: 67-71.
90. Hatae S, Mishima Y. Suppression of melanin production by bovine placental extract. Fragrance J. 1990;6:105-108.
91. Masuda M, Tejima T, Suzuki T, et al. Skin lighteners. Cosmet Toil. 1996;111:65-77.
92. Garcia A, Fulton JE Jr. The combination of glycolic acid and hydroquinone or kojic acid for treatment of melasma. Dermatol Surg. 1996;22:443-447. (Pubitemid 26153095)
93. Ellis DA, Tan AK, Ellis CS. Superfi cial Micropeels: Glycolic Acid and Alpha-Hydroxy Acid with Kojic Acid. Facial Plast Surg. 1995;11:15-21.
94. Lim JT. Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid. Dermatol Surg. 1999;25:282-284. (Pubitemid 29191314)
95. Shimogaki H, Tanaka Y, Tamai H, Masuda M. In vitro and in vivo evaluation of ellagic acid on melanogenesis inhibition. Int. J. Cosmet. Sci. 2000;22:291-303. (Pubitemid 30639205)
96. Kamide R, Arase S, Takiwaki H, et al. Clinical effects of XSC-29 formulation on UV-induced pigmentation. Nishinihon J Dermatol. 1995;57:136-142.
97. Ertam I, Mutlu B, Unal I, Alper S, Alper S, et al. Efficiency of ellagic acid and arbutin in melasma: a randomized, prospective, open-label study. J Dermatol. 2008;35:570-574.
98. Imokawa G, Yada Y, Miyagishi M. Endothelins secreted from human keratinocytes are intrinsic mitogens for human melanocytes. J Biol Chem. 1992;267:24675-24680.
99. Imokawa G, Kobayashi T, Miyagishi M, Higashi K, Yada Y. The role of endothelin-1 in epidermal hyperpigmentation and signaling mechanisms of mitogenesis and melanogenesis. Pigment Cell Res. 1997;10:218-228. (Pubitemid 127524184)
100. Ichihashi M, Kobayashi A, Okuda M, et al. Effect of chamomilla extracts application on UV-induced pigmentation. Skin Res (Hifu). 1999;41:475-480.
101. Kawashima M, Okuda M, Kobayashi A, et al. Inhibitory effect of chamomilla extracts on UV-induced pigmentation. Nishinihon J Dermatol. 1999;61:682-685.
102. Kim DS, Kim SY, Park SH, Choi YG, Kwon SB, et al. Inhibitory effects of 4-n-butylresorcinol on tyrosinase activity and melanin synthesis. Biol Pharm Bull. 2005;28: 2216-2219.
103. Katagiri T, Okubo T, Oyobikawa M, et al. Inhibitory action of 4-n-butylresorcinol (Rucinol ® ) on melanogenesis and its skin whitening effects. J Cosmet Chem Jpn. 2001;35: 42-49.
104. Mafune E, Morimoto Y, Iizuka Y. Tranexamic acid and melasma. Farumashia. 2008;44:437-442.
105. Chung WC, Shi GY, Chow YH, Chang LC, Hau JS, et al. Human plasmin induces a receptor-mediated arachidonate release coupled with G proteins in endothelial cells. Am. J. Physiol. 1993;264:C271-C281.
106. Wang N, Zhang L, Miles L, Hoover-Plow J. Plasminogen regulates pro-opiomelanocortin processing. J Thromb Haemost. 2004;2:785-796. (Pubitemid 40185717)
107. Lee JH, Park JG, Lim SH, Kim JY, Ahn KY, et al. Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: A preliminary clinical trial. Dermatol Surg. 2006;32:626-631. (Pubitemid 43742523)
108. Ando H, Matsui MS, Ichihashi M. Quasi-drugs developed in Japan for the prevention or treatment of hyperpigmentary disorders. Int J Mol Sci. 2010;11:2566-2575.
109. Kawashima M, Mizuno A, Murata Y. Improvement of hyperpigmentation based on accelerated epidermal turnover: Clinical effects of disodium adenosine monophosphate in patients with melasma. Jpn J Clin Dermatol. 2008;62:250-257.
110. Nakamura K, Yoshida M, Uchiwa H, et al. Down-regulation of melanin synthesis by a biphenyl derivative and its mechanism. Pigment Cell Res. 2003;16:494-500. (Pubitemid 37093026)
111. Takeda K, Yokota T, Ikemoto T, et al. Inhibitory effect of a formulation containing 0.5percent Magnolignan ® (5, 5 -dipropyl-biphenyl-2, 2-diol) on UV-induced skin pigmentation. Nishinihon J Dermatol. 2006;68:288-292. (Pubitemid 44014621)
112. Takeda K, Arase S, Sagawa Y, et al. Clinical evaluation of the topical application of Magnolignan ® (5, 5′ -dipropyl-biphenyl-2, 2′ -diol) for hyperpigmentation on the face. Nishinihon J Dermatol. 2006;68:293-298. (Pubitemid 44014622)
113. Bleehen SS. The treatment of hypermelanosis with 4- isopropylcatechol. Br J Dermatol. 1976;94:687-694.
114. Jimbow K. N-Acetyl-4-S-cysteaminylphenol as a new type of depigmenting agent for the treatment of patients with melasma. Arch Dermatol 1991;172:1528-1534.
115. Jimbow M, Marusyk H, Jimbow K. The in-vivo melanocytotoxicity and depigmenting potency of N-2, 4- acetoxyphenyl thioethyl acetamide in the skin and hair. Br J Dermatol. 1995;133:532-536.
116. Costa A, Moisé s TA, Cordero T, Alves CR, Marmirori J. Association of emblica, licorice and belides as an alternative to hydroquinone in the clinical treatment of melasma. An Bras Dermatol. 2010;85:613-620.
117. Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002;147:20-31. (Pubitemid 34779433)
118. Scherdin U, Bürger A, Bielfeldt S. Skin-lightening effects of a new face care product in patients with melasma. J Cosmet Dermatol. 2008;7:68-75. (Pubitemid 351228169)
119. Lee MH, Kim HJ, Ha DJ. Therapeutic effect of topical application of lenoliec acid and lincomycin in combination with betamethasone valerate in melasma patients. J Korean Med Sci. 2002;17:518-523.
120. Anonymous. The Wealth of India - Raw Materials Vols. I - XI (1948 - 76) and Vols 1-3 Revised Series (1985 - 92). New Delhi: Council of Scientifi c and Industrial Research.
121. Satyavati GV, Gupta AK, Tanabu N. Medicinal Plants of India Vol. 2 Council of Scientifi c and Industrial Research Publication. New Delhi: Indian Council of Medical Research, Cambridge printing worker; 1987. pp. XI + 557.
122. Draelos ZD. Topical agents used in association with cosmetic surgery. Sem Cut Med Surg. 1999;18:112-118. (Pubitemid 29262967)
123. Keller KL, Fenske NA. Use of vitamins A, C, and E and related compounds in dermatology: A review. J Am Acad Dermatol. 1998;39:611-625. (Pubitemid 28465885)
124. Handog EB, Galang DA, de Leon-Godinez MA, Chan GP. A randomized, double-blind, placebo-controlled trial of oral procyanidin with vitamins A, C, E for melasma among Filipino women. Int J Dermatol. 2009;48:896-901.
125. Grekin RC, Shelton RM, Geisse JK, Frieden I, et al. 510-nm pigmented lesion dye laser: Its characteristics and clinical uses. J Dermatol Surg Oncol. 1993;19:380-387. (Pubitemid 24175661)
126. Fitzpatrick RE, Goldman MP, Ruiz-Esparza J. Laser treatment of benign pigmented epidermal lesions using a 300 nanosecond pulse ad 510 nm wavelength. J Dermatol Surg Oncol. 1993;19:341-347. (Pubitemid 24175655)
127. Dinehart SM, Waner M, Flock S. The copper vapor laser for treatment of cutaneous vascular and pigmented lesions. J Dermatol Surg Oncol. 1993;19:370-375. (Pubitemid 24175659)
128. Goldberg DJ. Benign pigmented lesions of the skin: Treatment with Q- switched ruby laser. J Dermatol Surg Oncol. 1993;19:376-379. (Pubitemid 24175660)
129. Manaloto RM, Alster T. Erbium YAG resurfacing for refractory melasma. Dermatol Surg. 1999;25:121-123. (Pubitemid 30195951)
130. Negishi K, Kushikata N, Takeuchi K. Photorejuvenation by intense pulsed light with objective measurement of skin color in Japanese patients. Dermatol Surg. 2006;32: 1380-1387. (Pubitemid 44691144)
131. Jeong SY, Chang SE, Bak H. New melasma treatment by collimated low fl uence Q-switched Nd:YAG laser. Korean J Dermatol. 2008;46:1163-1170.
132. Chan NP, Ho SG, Shek SY. A case series of facial depigmentation associated with low fl uence Q-switched 1,064nm Nd:YAG laser for skin rejuvenation and melasma. Lasers Surg Med. 2010;42:712-719.
133. Polnikorn N. Treatment of refractory dermal melasma with the MedLite C6 Q-switched Nd:YAG laser: two case reports. J Cosmet Laser Ther. 2008;10:167-173.
134. Cho SB, Kim JS, Kim MJ. Melasma treatment in Korean women using a 1064-nm Q-switched Nd:YAG laser with low pulse energy. Clin Exp Dermatol. 2009;34:e847 - 850.
135. Lee HS, Won CH, Lee DH, et al. Treatment of melasma in Asian skin using a fractional 1,550-nm laser: An open clinical study. Dermatol Surg. 2009;35:1499-1504.
136. Kroon MW, Wind BS, Beek JF, et al. Nonablative 1550-nm fractional laser therapy versus triple topical therapy for the treatment of melasma: A randomized controlled pilot study. J Am Acad Dermatol. 2011;64:516-523.
137. Lee HI, Lim YY, Kim BJ, et al. Clinicopathologic efficacy of copper bromide plus/yellow laser (578 nm with 511 nm) for treatment of melasma in Asian patients. Dermatol Surg. 2010;36:885-893.
138. Dawber RPR, Walker NPJ. Physical and Surgical therapy. In: Champion RH, Burns BA, editors. Text book of Dermatology. 6th ed. London: Blackwell Scientifi c Publications; 1998. pp. 3573 - 3575.
139. Cotellessa C, Peris K, Fargnoli MC, et al. Microdermabrasion vs Microdermabrasion followed by 15% TCA for treatment of cutaneous hyperpigmentation in adult females. Dermatol Surg. 2003;29:352-356. (Pubitemid 36417447)
140. Moy LS, Murad H, Moy RL. Superfi cial chemical peels, in Cutaneous Surgery. In: Wheeland RG, ed. 1st ed. Philadelphia: WB Saunders company. 1994. pp. 463 - 478.
141. Kodali S, Guevara IL, Carrigan CR, et al. A prospective, randomized, split-face, controlled trial of salicylic acid peels in the treatment of melasma in Latin American women. J Am Acad Dermatol. 2010;63:1030-1035.
142. Monheit GD. The Jessner' s - trichloroacetic acid peel. An enhanced medium-depth chemical peel. Dermatol Clin. 1995;13:277-283.
143. Sarkar R, Kaur C, Bhalla M, Kanwar AJ. The combination of glycolic acid peels with a topical regimen in the treatment of Melasma in dark skinned patients. Dermatol Surgery. 2002;28:828-832. (Pubitemid 35014686)
144. Hurley ME, Guevara IL. Gonzales RM, et al. Effi cacy of glycolic acid peels in treatment of melasma. Arch Dermatol 2002;138:1578-1582. (Pubitemid 35453470)
145. Sehgal VN, Luthra A, Aggarwal AK. Evaluation of graded strength glycolic acid (GA) facial peel: an Indian experience. J Dermatol. 2003;30:758-761. (Pubitemid 37370234)
146. Gupta AK, Gover MD, Nouri K, et al. The treatment of melasma: a review of clinical trials. J Am Acad Dermatol. 2006;55:1048-1065. (Pubitemid 44716465)
147. Grimes PE. The safety and effi cacy of salicylic acid chemical peels in darker racial-ethnic groups. Dermatol Surg. 1999;25:18-22. (Pubitemid 29242727)
148. Kodali S, Guevara IL, Carrigan CR, Daulat S, Blanco G, et al. A prospective, randomized, split-face, controlled trial of salicylic acid peels in the treatment of melasma in Latin American women. J Am Acad Dermatol. 2010;63: 1030-1035.
149. Ejaz A, Raza N, Iftikhar N, Muzzafar F. Comparison of 30% salicylic acid with Jessner's solution for superfi cial chemical peeling in epidermal melasma. J Coll Physicians Surg Pak. 2008;18:205-208. (Pubitemid 351802916)
150. Sarkar R, Kaur C, Bhalla M, Kanwar AJ. The combination of glycolic acid peels with a topical regimen in the treatment of melasma in dark-skinned patients: a comparative study. Dermatol Surg. 2002;28:828-832. (Pubitemid 35014686)
151. Erbil H, Sezer E, Tastan B, Arca E, Kurumlu Z. Efficacy and safety of serial glycolic acid peels and a topical regimen in the treatment of recalcitrant melasma. J Dermatol. 2007;34:25-30. (Pubitemid 46005953)
152. Lim JT, Tham SN. Glycolic acid peels in the treatment of melasma among Asian women. Dermatol Surg. 1997;23: 177-179. (Pubitemid 27200622)
153. Rendon M, Cardona LM, Bussear EW, Benitez AL, Col ó n LE, Johnson LA, et al. Successful treatment of moderate to severe melasma with triple-combination cream and glycolic acid peels: a pilot study. Cutis. 2008;82: 372-378.
154. Hurley ME, Guevara IL, Gonzales RM, Pandya AG. Efficacy of glycolic acid peels in the treatment of melasma. Arch Dermatol. 2002;138:1578-1582. (Pubitemid 35453470)
155. Kalla G, Garg A, Kachhawa D. Chemical peeling-glycolic acid versus trichloroacetic acid in melasma. Indian J Dermatol Venereol Leprol. 2001;67:82-84. (Pubitemid 33313795)
156. Soliman MM, Ramadan SA, Bassiouny DA, et al. Combined trichloroacetic acid peel and topical ascorbic acid versus trichloroacetic acid peel alone in the treatment of melasma: a comparative study. J Cosmet Dermatol. 2007;6:89-94. (Pubitemid 46845417)
157. Sharquie KE, Al-Tikreety MM, Al-Mashhadani SA. Lactic acid chemical peels as a new therapeutic modality in melasma in comparison to Jessner's solution chemical peels. Dermatol Surg. 2006;32:1429-1436. (Pubitemid 44934890)
158. Lawrence N, Cox SE, Brody HJ. Treatment of melasma with Jessner's solution versus glycolic acid: A comparison of clinical efficacy and evaluation of the predictive ability of Wood's light examination. J Am Acad Dermatol. 1997;36:589-593. (Pubitemid 27164492)
159. Khunger N, Sarkar R, Jain RK. Tretinoin peels versus glycolic acid peels in the treatment of melasma in dark-skinned patients. Dermatol Surg. 2004;30:756-760. (Pubitemid 38657969)
160. Ilknur T, Biçak MU, Demirtasoǧlu M, et al. Glycolic acid peels versus amino fruit acid peels in the treatment of melasma. Dermatol Surg. 2010;36:490-495.
161. Berardesca E, Cameli N, Primavera G, et al. Clinical and instrumental evaluation of skin improvement after treatment with a new 50% pyruvic acid peel. Dermatol Surg. 2006;32: 526-531.